-
1.发明申请USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME 审中-公开作为生物标记用于预防神经损伤性疾病和治疗的AKT磷酸化的使用
公开(公告)号：WO2012160563A3
公开(公告)日：2014-05-08
申请号：PCT/IL2012050185
申请日：2012-05-23
Applicant: YEDA RES & DEV , UNIVERSITÄTSKLINIKUM HAMBURG EPPENDORF , OVADIA ERAN , COHEN IRUN R , HERKEL JOHANNES , MARGALIT RAANAN , PEVSNER-FISCHER MEIRAV
Inventor： OVADIA ERAN , COHEN IRUN R , HERKEL JOHANNES , MARGALIT RAANAN , PEVSNER-FISCHER MEIRAV
IPC: A61K39/00
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
Abstract translation: 本发明涉及包含选自SEQ ID NO：1，SEQ ID NO：2，其类似物和衍生物的氨基酸序列的肽用于治疗神经变性疾病如肌萎缩性侧索硬化（ ALS）。 本发明还提供了评估对本发明的肽的治疗反应性的方法。 此外，本发明涉及使用Akt和磷酸化Akt作为生物标志物的ALS进展的预后。
-
2.发明申请USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME 审中-公开作为生物标记用于预防神经损伤性疾病和治疗的AKT磷酸化的使用
公开(公告)号：WO2012160563A2
公开(公告)日：2012-11-29
申请号：PCT/IL2012/050185
申请日：2012-05-23
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. , OVADIA, Eran , COHEN, Irun R. , HERKEL, Johannes , MARGALIT, Raanan , PEVSNER-FISCHER, Meirav
Inventor： OVADIA, Eran , COHEN, Irun R. , HERKEL, Johannes , MARGALIT, Raanan , PEVSNER-FISCHER, Meirav
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
Abstract translation: 本发明涉及包含选自SEQ ID NO：1，SEQ ID NO：2，其类似物和衍生物的氨基酸序列的肽用于治疗神经变性疾病如肌萎缩性侧索硬化（ ALS）。 本发明还提供了评估对本发明的肽的治疗反应性的方法。 此外，本发明涉及使用Akt和磷酸化Akt作为生物标志物的ALS进展的预后。
-
Patent Agency Ranking3.发明申请COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS 审中-公开HSP60肽组成和病毒抗生素用于疫苗接种和诊断
公开(公告)号：WO2006097914A2
公开(公告)日：2006-09-21
申请号：PCT/IL2006/000222
申请日：2006-02-21
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE , B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. , COHEN, Irun, R , RAGER-ZISMAN, Bracha , PORGADOR, Angel , HERKEL, Johannes
Inventor： COHEN, Irun, R , RAGER-ZISMAN, Bracha , PORGADOR, Angel , HERKEL, Johannes
IPC: A61K39/12
CPC classification number: A61K47/4833 , A61K47/646 , A61K2039/6043 , A61K2039/64 , C07K14/005 , C12N2770/24122 , G01N33/56983 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/53 , Y02A50/60
Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.
Abstract translation: 本发明提供了包含分离的病毒抗原肽和衍生自HSP60的T细胞表位的合成肽的改进的疫苗。 本发明包括其中肽用作佐剂以及其中肽与病毒抗原共价连接的缀合物的混合物。 已知的合成肽载体p458为合成的病毒表位和类似物提供显着改善的免疫原性。 Ec27是从HSP60衍生的新型肽，其作为混合物或共价缀合物增加了病毒抗原的免疫原性。 一些分离的病毒表位是新的，并且被要求用于诊断以及治疗或预防用途。
-
4.发明申请NANOPARTICLE COMPOSITIONS FOR GENERATION OF REGULATORY T CELLS AND TREATMENT OF AUTOIMMUNE DISEASES AND OTHER CHRONIC INFLAMMATORY CONDITIONS 审中-公开用于产生调节性T细胞的纳米颗粒组合物和治疗自身免疫性疾病和其他慢性炎症病症
公开(公告)号：WO2013072051A1
公开(公告)日：2013-05-23
申请号：PCT/EP2012/004735
申请日：2012-11-14
Applicant: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF , FREUND, Barbara , HEEREN, Jörg , NIELSEN, Peter , CARAMBIA, Antonella , HERKEL, Johannes , BRUNS, Oliver , LOHSE, Ansgar , LÜTH, Stefan , WELLER, Horst , SALMEN, Sunhild , UNIVERSITÄT HAMBURG , HEINRICH-PETTE-INSTITUT
Inventor： FREUND, Barbara , HEEREN, Jörg , NIELSEN, Peter , CARAMBIA, Antonella , HERKEL, Johannes , BRUNS, Oliver , LOHSE, Ansgar , LÜTH, Stefan , WELLER, Horst , SALMEN, Sunhild
CPC classification number: A61K9/146 , A61K9/0019 , A61K9/1075 , A61K39/0008 , A61K39/39 , A61K47/6907 , A61K49/0067 , A61K49/1809 , A61K49/1857 , A61K51/1227 , A61K2039/55555 , C12N5/0637 , C12N2502/14
Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.
Abstract translation: 本发明涉及用于将抗原靶向递送至肝细胞，特别是肝窦内皮细胞（LSEC）和/或枯否细胞的纳米颗粒，并且用于体内产生调节性T细胞，特别是CD4 + CD25 + FOXP3 +调节 T细胞（Treg）。 本发明提供了用于预防和治疗自身免疫性疾病，过敏或其它慢性炎性病症以及用于产生调节性T细胞的药物组合物和方法。 本发明中使用的纳米颗粒包含a）包含使得纳米颗粒水溶性的两亲聚合物的胶束，和b）包含与胶束外部相关联的至少一个T细胞表位的肽。 胶束可以或可以不包含固体疏水性核心。
-
5.发明申请COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS 审中-公开HSP60肽组成和病毒抗生素用于疫苗接种和诊断
公开(公告)号：WO2006097914A3
公开(公告)日：2007-01-04
申请号：PCT/IL2006000222
申请日：2006-02-21
Applicant: YEDA RES & DEV , B G NEGEV TECHNOLOGIES AND APP , COHEN IRUN R , RAGER-ZISMAN BRACHA , PORGADOR ANGEL , HERKEL JOHANNES
Inventor： COHEN IRUN R , RAGER-ZISMAN BRACHA , PORGADOR ANGEL , HERKEL JOHANNES
CPC classification number: A61K47/4833 , A61K47/646 , A61K2039/6043 , A61K2039/64 , C07K14/005 , C12N2770/24122 , G01N33/56983
Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.
Abstract translation: 本发明提供了包含分离的病毒抗原肽和衍生自HSP60的T细胞表位的合成肽的改进疫苗。 本发明包括其中肽用作佐剂以及其中肽与病毒抗原共价连接的缀合物的混合物。 已知的合成肽载体p458为合成的病毒表位和类似物提供显着改善的免疫原性。 Ec27是从HSP60衍生的新型肽，其作为混合物或共价缀合物增加了病毒抗原的免疫原性。 一些分离的病毒表位是新的，并且被要求用于诊断以及治疗或预防用途。
-
公开(公告)号：WO2006021954A3
公开(公告)日：2006-03-02
申请号：PCT/IL2005/000908
申请日：2005-08-23
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. at the Weizmann Institute of Science , HERKEL, Johannes , COHEN, Irun R , ROTTER, Varda , LOHSE, Ansgar W , EREZ, Neta , MIMRAN, Avishai , KAM, Na'aman
Inventor： HERKEL, Johannes , COHEN, Irun R , ROTTER, Varda , LOHSE, Ansgar W , EREZ, Neta , MIMRAN, Avishai , KAM, Na'aman
IPC: A61K38/10
Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides.
-
公开(公告)号：WO2006021954A2
公开(公告)日：2006-03-02
申请号：PCT/IL2005000908
申请日：2005-08-23
Applicant: MANN INST OF SCIENCE YEDA RES , HERKEL JOHANNES , COHEN IRUN R , ROTTER VARDA , LOHSE ANSGAR W , EREZ NETA , MIMRAN AVISHAI , KAM NA AMAN
Inventor： HERKEL JOHANNES , COHEN IRUN R , ROTTER VARDA , LOHSE ANSGAR W , EREZ NETA , MIMRAN AVISHAI , KAM NA AMAN
IPC: A61K38/10
CPC classification number: A61K39/0008 , A61K38/00 , A61K39/0005 , C07K7/06 , C07K7/08 , C07K14/435
Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides.
Abstract translation: 本发明涉及能够抑制真核细胞中的细胞和免疫应答反应的肽。 本发明提供了使用由单克隆抗DNA抗体识别的肽，具有抗凋亡和抗炎活性的肽来治疗人退行性疾病和炎症的组合物和方法。 本发明还提供抗体分子及其用于分离这些肽的用途。
-
-
-
-
-
-
Search Results
7
records
(took 0.01 seconds)
